Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 studyMartin Hutchings, Pieternella J. Lugtenburg, Rogier Mous et al.|The Lancet|2021Cited by 337
Venetoclax plus R- or G-CHOP in non-Hodgkin lymphoma: results from the CAVALLI phase 1b trialAndrew D. Zelenetz, Franck Morschhauser, Gilles Salles et al.|Blood|2019Cited by 136
Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): a phase 2 cohort of a single-arm, multicentre studyKim Linton, Julie M. Vose, Diana Gernhardt et al.|The Lancet Haematology|2024Cited by 134
A soluble form of the human T cell differentiation antigen CD27 is released after triggering of the TCR/CD3 complexRogier Q. Hintzen, René A. W. van Lier, Rolien de Jong et al.|The Journal of Immunology|1991Cited by 128
Rituximab and the risk of transformation of follicular lymphoma: a retrospective pooled analysisMassimo Federico, Bertrand Coiffier, María Dolores Caballero Barrigón et al.|The Lancet Haematology|2018Cited by 116